Shares of the pharmaceutical giant, Merck, plunged 10% today on news that the FDA has rejected the company’s new cholesterol drug, Cordaptive.
The company’s stock has been battered in recent months, dropping about 36% since December.
The Cordaptive snub has deepened Merck’s recent decline but, this is no death sentence.
Prognosis: Bruised but not broken…shout out to Joss Stone for a great song :)
Where talk is money.
Written by Tisa Silver [email] for b5media.
Accounting Solver
Behind The Buzz
Biz Chicks Rule
Biz Levity
Boss Hatch
Brandcurve
Business & Blogging
Buzz Networker
Common Sense PR
Contract Worker
Copyblogger
Daily Blender
Digital Money World
Doing Biz Abroad
Everyday Networker
Franchise Pick
Greener Assets
Home Biz Notes
Interview Chatter
Just Make Money Online
Leadership Turn
LifeDev
My Organized Biz
One Vote Matters
Pimp Your Work
Project Management 411
Property Crossroads
Second Life Pros
Slacker Manager
Small Business Boomers
Startup Spark
Successful Blog
Talk Stock Trading
Taxgirl
The 501(c) Files
The Golden Pencil
Work Boxers
Yielding Wealth
0 opinions for Merck takes a tumble on FDA rejection news
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: